Screening and treating 456 people for H. pylori could prevent one gastric cancer case.¹
Achieving this impact at a population level depends on reliable infection surveillance, something that becomes much more difficult when studies span dozens of locations and thousands of participants.
In the webinar Nationwide Scaling of Infection Surveillance: A Reproducibility Case Study, the 2025 JoVE Researcher Innovation Award winner Dr Liang Wang and coauthor Dr Alfred Tay showed what that takes in practice.
Their China MAP project used one noninvasive string test and qPCR workflow across 26 provinces, 52 cities, and almost 13,000 individuals. The study results — an urban H. pylori prevalence of 27% and antibiotic resistance rates up to 51% — have direct implications for treatment decisions.²